Genfit stock slides 4.5%, among the largest declines on the SBF 120
The Lille-based biotech retreats during midday trading and joins the bottom of the Paris index. The decline occurs in a French market under pressure, while short positions on the stock have increased significantly in recent weeks.
A support level broken after a month of continuous correction
The Genfit share falls 4.28% to €8.73 and drops below the €8.92 threshold, which reports from October 5 and 7 described as under pressure. This threshold held up during Monday's session before giving way this morning. The decline adds to a loss of 35.7% over one month, and the price is 9.1% below its 200-day moving average, still below the 20 and 50-day averages.
The RSI at 32 remains close to oversold territory without entering it. Genfit ranks among the largest declines on the SBF 120, which is down 0.77%, while the CAC 40 declines 0.72%.
Short positions showing sharp progression on the stock
According to filed declarations, three funds hold 2.14% of capital in net short positions, with this level formed in barely thirty days. This rapid increase indicates that institutional investors are positioning themselves downward on the stock or seeking to hedge an exposure, though their motivations remain unclear. The figure remains modest in absolute value, but its one-month progression warrants monitoring.
Over one year, the stock nonetheless shows a gain of 154.8%, leaving the value well above its level from twelve months ago, despite the recent decline. This decline has extended over the quarter, with a 35.1% loss, and the nearest resistance level sits at €14.52.
